Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche, Toyama Enter Licensing Pact Worth Up To $370M (Japan)

This article was originally published in PharmAsia News

Executive Summary

Drugmaker Roche Holding AG Monday said it entered an agreement with Toyama Chemical Co. of Japan to develop a potential new drug for the treatment of rheumatoid arthritis in a deal worth up to $370 million. Roche expects its emerging franchise of treatments for rheumatoid arthritis and other automimmune disease to become an important driver for growth over the next few years. It launched its first treatment for the diseases last year, and has another in late-stage development, which it hopes to start selling from next year. Toyama's experimental drug, codenamed T-5224, is in the first of three phases of clinical testing. By inhibiting a specific inflammatory process, T-5224 has the potential to block signs and symptoms of rheumatoid arthritis as well as the progressive destruction of joint and bone, Roche said. Toyama Chemical has granted Roche exclusive rights to research, develop, and sell T-5224 outside Japan, where Toyama Chemical will retain exclusive rights. (Click here for more - May Require Paid Subscription

You may also be interested in...

Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR - How To Survive Changing And Confusing Times

May 26 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts